Saturday, 17 October 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

NORDIC NANOVECTOR Stock Went Up By Over 33% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of NORDIC NANOVECTOR (Oslo Børs Benchmark Index_GI: NANOV.OL) jumped by a staggering 33.1% in 21 sessions from kr1.45 to kr1.93 at 08:37 EST on Wednesday, after five consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI is jumping 0.33% to kr1,205.68, after three successive sessions in a row of gains.

NORDIC NANOVECTOR's last close was kr1.62, 51.47% below its 52-week high of kr3.34.

About NORDIC NANOVECTOR

Thor Medical AS produces alpha-emitters for radiopharmaceuticals to treat cancer. The company was incorporated in 2017 and is based in Oslo, Norway.

Earnings Per Share

As for profitability, NORDIC NANOVECTOR has a trailing twelve months EPS of kr-2.41.

More news about NORDIC NANOVECTOR (NANOV.OL).

Categories

stockMarket

Tags

Stock PriceMarket Session NowStock Market NowPrice UpMarket SessionStock Price UpNANOV.OLNORDIC NANOVECTORStock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,384 source documents archived
Query this data → isubstrate.com